Correction: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024

MFN Publicerad: 25 Apr 16:30

This is a correction of the press release published on 27 March 2025 at 08:30 CET, titled “Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024”

In the previously published press release, it was incorrectly stated that the attached year-end report for 2024 had been reviewed by the company’s auditors. This is not correct – the report had not been subject to auditor review at the time of publication.

The correct version of the Q4 report is attached to this press release.

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at [email protected] or +46 (0)8-580 065 99.

Börskollen

För dig med koll på börsen

Pressmeddelande

Correction: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024

Bifogade filer

Nyheter om Magle Chemoswed

Läses av andra just nu

Om aktien Magle Chemoswed

Senaste nytt